Mold-Tek Packaging Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MOLDTKPAC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mold-Tek Packaging reported FY25 revenue of Rs 781.32 crore, up 11.83% from Rs 698.65 crore last year, driven by 7.30% growth in sales volume to 38,264 MT. EBITDA rose 6.98% to Rs 143.83 crore, but PAT declined 9.05% to Rs 60.55 crore due to sharply higher finance costs (up ~89% to Rs 13.90 crore) and depreciation (up ~26% to Rs 48.69 crore). For Q4, revenue grew 14.55% to Rs 202.61 crore and EBITDA rose 9.21% to Rs 39.08 crore, while net profit fell 9.47% to Rs 16.23 crore. The newly-launched Pharma-Pack division crossed break-even in Q4 with sales tripling sequentially, and capacity expansion is ongoing across paints, IML printing, and pharma segments.
Mixed signals for shareholders — top-line growth is healthy and the pharma break-even is a positive long-term trigger, but bottom-line pressure from rising finance and depreciation costs and a 37% jump in borrowings (to Rs 181 crore) may weigh on near-term sentiment. The auditor issued an unmodified (clean) opinion, and an interim dividend of Rs 2 per share was already paid during the year.